RESUMO
Background: This study aimed to investigate the effects of omega-3 fatty acid use on sepsis and mortality in patients treated for COVID-19 disease in the intensive care unit (ICU) based on clinical and laboratory results. Aim: To determine the effect of omega-3 fatty acid use on sepsis and mortality in patients with COVID-19. Patients and Methods: A total of 80 patients with confirmed COVID-19 infection who were hospitalized in the ICU of Ankara City Hospital, received (n = 40) or did not receive (n = 40) omega-3 fatty acid dietary supplementation, were included in this single-center, retrospective study. The clinical and laboratory data of eligible patients were extracted from the hospital records. Results: The mean age was 65.5 (13.6). The mean length of stay in the intensive care unit was 11.5 (6.3) days. Mortality and sepsis development rates were similar in the groups. The frequency of patients who received pulse steroid therapy was higher in the group of patients who did not receive omega-3 (P < 0.05). Hypertension was more common in the patient group receiving omega-3 supplements (P < 0.05). Mean procalcitonin and interleukin-6 (IL-6) levels were significantly lower in patients who received omega-3 supplements compared to those who did not receive supplements (P < 0.001 and P < 0.05). Mean prothrombin time (PT) was shorter in patients receiving omega-3 supplementation (P < 0.05). Conclusions: Study results obtained in this study indicate that providing omega-3 fatty acid supplements may be beneficial to patients with severe COVID-19, however further research with large-scale randomized controlled trials is necessary.
